{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhi L"],"funding":["Henan Program for Science and Technology Development","Talent Support Program of Xinxiang Medical University"],"pagination":["337"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11853679"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Background</h4>Chimeric antigen receptor (CAR) engineered natural killer (NK) cells have shown their efficacy and superiority against cancer and possess the potential to become off-the-shelf immunotherapy products. Nonetheless, some challenges associated with CAR-NK cells still exist including inhibitory receptor engagement, antigen escape, and inadequate activation.<h4>Methods</h4>Given this, based on the concept of synthetic biology, we rationally designed a novel dual-targeted CAR (dtCAR), primarily comprising PD-L1 nanoantibody (PD-L1<sup>Nb</sup>) and NKG2D as the ectodomain, transmembrane and cytoplasmic domains (CP) of CD28, and the CP of 4-1BB and CD3ζ. NK92 cells were engineered to express this third-generation of dtCAR. We then elucidated the role of dtCAR-modified NK92 cells"],"journal":["BMC cancer"],"pubmed_title":["CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models."],"pmcid":["PMC11853679"],"funding_grant_id":["XYBSKYZZ201924","232102311042"],"pubmed_authors":["Gao Q","Zhi L","Zhang Z","He W","Niu Z","Guo C","Zhu W","Wang Y","Shang C"],"additional_accession":[]},"is_claimable":false,"name":"CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.","description":"<h4>Background</h4>Chimeric antigen receptor (CAR) engineered natural killer (NK) cells have shown their efficacy and superiority against cancer and possess the potential to become off-the-shelf immunotherapy products. Nonetheless, some challenges associated with CAR-NK cells still exist including inhibitory receptor engagement, antigen escape, and inadequate activation.<h4>Methods</h4>Given this, based on the concept of synthetic biology, we rationally designed a novel dual-targeted CAR (dtCAR), primarily comprising PD-L1 nanoantibody (PD-L1<sup>Nb</sup>) and NKG2D as the ectodomain, transmembrane and cytoplasmic domains (CP) of CD28, and the CP of 4-1BB and CD3ζ. NK92 cells were engineered to express this third-generation of dtCAR. We then elucidated the role of dtCAR-modified NK92 cells","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-05-24T03:15:31.198Z","creation":"2025-04-04T02:11:02.684Z"},"accession":"S-EPMC11853679","cross_references":{"pubmed":["40000974"],"doi":["10.1186/s12885-025-13780-2"]}}